CAMP4 Therapeutics Is Maintained at Buy by Chardan Capital
Ratings actions from Benzinga: GMT) CAMP4 Therapeutics Price Target Cut to $6.00/Share From $6.50 by Chardan CapitalRatings actions from Benzinga
Ratings actions from Benzinga: GMT) CAMP4 Therapeutics Price Target Cut to $6.00/Share From $6.50 by Chardan CapitalRatings actions from Benzinga